Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC67529 | DM4-SMCC |
DM4-SMCC is an antibody-drug conjugate (ADC) payload that combines the potent antitubulin agent DM4 with a non-cleavable SMCC linker. This conjugate is designed to deliver cytotoxic effects specifically to tumor cells, leveraging DM4's ability to disrupt microtubule dynamics. The stable SMCC linker ensures controlled drug release, enhancing the ADC's antitumor activity while minimizing off-target toxicity.
More description
|
![]() |
DC66368 | sulfo-SPDB-DM4 Featured |
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
More description
|
![]() |
DC8539 | DM1-SMCC Featured |
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate.
More description
|
![]() |
DC31389 | SGD-1269(MCMMAF) Featured |
Mafodotin, also known as mc-MMAF and SGD-1269 or Maleimidocaproyl monomethylauristatin F, is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful a
More description
|
![]() |
DC50025 | Deruxtecan Featured |
Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate.
More description
|
![]() |
DC39818 | CL2-SN-38(DCA) Featured |
CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 (Item No. 15632) and a maleimidocaproyl linker.1 CL2-SN-38 has been linked to tumor-selective human monoclonal antibodies, such as anti-CEACAM5 (hMN-14) to target SN-38 to tumor sites and improve its solubility. CL2-SN-38 linked to hMN-14 binds (Kd = 1.4 nM) and is cytotoxic to LoVo human colon adenocarcinoma cells (IC50 = 5.3 nM). CL2-SN-38 linked to hMN-14 increases survival in a colon carcinoma mouse model of lung metastasis.
More description
|
![]() |
DC7556 | VcMMAE Featured |
VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
More description
|
![]() |
DC72886 | Dox-btn2 Featured |
Dox-btn2 is a biotinylated derivative of Doxorubicin, with a biotin label at the point of conjugation to doxorubicin at 3'-NH2. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm.
More description
|
![]() |
DC40833 | MC-VC-PAB-Azide Featured |
MC-VC-PAB-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DCC1837 | Dolastatin 10 Featured |
Highly potent cytotoxic microtubule inhibitor
More description
|
![]() |
DC11013 | Tesirine |
Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload.
More description
|
![]() |
DC42455 | Acetylene-linker-Val-Cit-PABC-MMAE Featured |
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.
More description
|
![]() |
DC71950 | Ac-Lys-Val-Cit-PABC-MMAE Featured |
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.
More description
|
![]() |
DC49346 | Bi-Mc-VC-PAB-MMAE Featured |
Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.
More description
|
![]() |
DC47680 | PSMA-Val-Cit-PAB-MMAE Featured |
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.
More description
|
![]() |
A273 | Datopotamab deruxtecan Featured |
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.
More description
|
![]() |
A125 | Trastuzumab deruxtecan Featured |
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
More description
|
![]() |
A124 | Trastuzumab emtansine Featured |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.
More description
|
![]() |
DC80073 | Azido-PEG4-EV-Cit-PAB-MMAE Featured |
Azido-PEG4-EV-Cit-PAB-MMAE is a precursor of antibody drug conjugate.
More description
|
![]() |
DC47754 | Disitamab vedotin Featured |
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin enhances antitumor immunity.
More description
|
![]() |
DC74470 | SuO-Val-Cit-PAB-MMAE Featured |
A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
More description
|
![]() |
DC40614 | Maleimide-DOTA Featured |
Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC8461 | Mc-Val-Cit-PABC-PNP(VCMMAE linker) Featured |
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker.
More description
|
![]() |
DC71115 | SN38 NHS ester Featured |
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC41151 | Boc-Dap-NE Featured |
Boc-Dap-NE, a dipeptide, is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC42440 | Fmoc-Gly-Gly-Phe-OH Featured |
Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC7021 | Monomethyl auristatin E (vedotin) Featured |
Monomethyl auristatin E (MMAE; Vedotin) is a hot topic in Antibody-drug conjugates (ADCs) studies. It is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.
More description
|
![]() |
DC40590 | DBCO-PEG4-MMAF Featured |
DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.
More description
|
![]() |
DC46408 | Gly3-VC-PAB-MMAE Featured |
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC46199 | DBCO-PEG4-Ahx-DM1 Featured |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.
More description
|
|